Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459660) titled 'An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis' on March 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: MapLight Therapeutics
Condition:
Psychosis Associated With Alzheimer's Disease
Intervention:
Drug: ML-007C-MA
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 2026
Target Sample Size: 210
To know more, visit https://clinicaltrials.gov/study/NCT07459660
Published by HT Digital Content Services with permiss...